Such a re-sensitizing effect was also observed in additional models for other ABCG2 substrates, including topotecan, mitoxantrone, and pevonedistat, further highlighting the potential of combined therapy with SCO-101 in counteracting MDR in cancer. This evidence concerns the gene ABCG2 and cancer.